TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ketamine Improves Post-Thoracotomy Analgesia
Brief Summary: Thoracotomy for lung tumor or for minimally invasive direct coronary artery bypass (MIDCAB) surgery, may be associated with debilitating pain. Ketamine was shown to enhance opioid antinociception and prevent opioid resistance. We hypothesize that ketamine given with morphine would lower morphine consumption and narcotic related side effects after thoracotomy and provide superior analgesia to morphine given alone.


Options:
A: Arm Label: C group; Type: PLACEBO_COMPARATOR; Interventions: Drug: NS infusion | Arm Label: KET group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine infusion | Intervention Type: DRUG; Name: Ketamine infusion; Assigned to Arm(s): KET group | Intervention Type: DRUG; Name: NS infusion; Assigned to Arm(s): C group
B: Arm Label: S(+)-ketamine group (SG); Type: ACTIVE_COMPARATOR; Interventions: Drug: S(+)-Ketamine | Arm Label: placebo group (PG); Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: S(+)-Ketamine; Assigned to Arm(s): S(+)-ketamine group (SG)
C: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine
D: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Brief Summary: Modafinil, trade named Provigil, is a medication approved by the Food and Drug Administration for the treatment of narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Each of these problems is characterized by difficulty sleeping at night and excessive daytime sleepiness. Modafinil is prescribed during the day to counteract this sleepiness. The idea behind this treatment is that sleepiness that leads to napping during the day prevents a patient from being tired or sleepy enough to get good sleep at night. This study is designed to determine if the medication can "reset" participants' sleep/wake rhythm to a more normal rhythm.


Options:
A: Arm Label: SAR110894 - 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 2 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (for SAR110894), Drug: Donepezil | Intervention Type: DRUG; Name: SAR110894; Assigned to Arm(s): SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg | Intervention Type: DRUG; Name: placebo (for SAR110894); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): Placebo, SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg
B: Arm Label: Modafinil; Type: EXPERIMENTAL; Interventions: Drug: modafinil | Intervention Type: DRUG; Name: modafinil; Assigned to Arm(s): Modafinil
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Melatonin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Melatonin 5 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Melatonin 5 mg; Assigned to Arm(s): Melatonin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Brief Summary: In this double-blinded, placebo-controlled, fixed-dose, study patients will be randomly assigned to take placebo or 20 mg tadalafil thrice weekly for 6 weeks. After 6 weeks a wash out period of 2 week will be observed and then the two groups will be switched over to receive the other drug. We planned a priori to include 20 patients. The concomitant medication for treatment of rheumatic disease remained unchanged during the whole study. Patient will undergo clinical and lab evaluation for organ damage for kidney and lungs. ECHO heart will be done at base line to assess the PAH and LV function and repeated at the end of the study. Blood pressure will be recorded at each visit. A physician unaware of the treatment group will record skin score and appearance of new cutaneous ulcers. The primary outcome variables will be frequency and duration of Raynauds attacks, evolution of trophic digital lesions and change in flow mediated dilatation of the brachial artery. Flow mediated dilatation of the brachial artery will be done at baseline 6 and 12 weeks.


Options:
A: Arm Label: Sildenafil 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 80 mg | Arm Label: Sildenafil 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 40 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil 40 mg; Assigned to Arm(s): Sildenafil 40 mg | Intervention Type: DRUG; Name: Sildenafil 80 mg; Assigned to Arm(s): Sildenafil 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Amlodipine-Udenafil (AU) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Arm Label: Udenafil-Amlodipine (UA) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Intervention Type: DRUG; Name: Udenafil or Amlodipine; Assigned to Arm(s): Amlodipine-Udenafil (AU) arm, Udenafil-Amlodipine (UA) arm
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Placebo
D: Arm Label: Vardenafil 10 mg bid; Type: EXPERIMENTAL; Interventions: Drug: vardenafil, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: vardenafil, Drug: Placebo | Intervention Type: DRUG; Name: vardenafil; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Programs of Coordinated Care and Disease Management
Brief Summary: This is a Congressionally mandated study. In the original study, 16 demonstration programs provided care coordination services to beneficiaries with chronic illness in Medicare's fee-for-service program. A five-year CMS-funded study tested whether the programs can improve patients' use of medical services, improve patients' outcomes and satisfaction with care, and reduce Medicare costs. The study also assessed physicians' satisfaction with the programs.

In 2008 Congress extended the project for two of the original programs--Mercy Medical Center - North Iowa and Health Quality Partners in Pennsylvania--and they will enroll Medicare beneficiaries and provide care coordination services into the spring of 2010.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Shared decision making | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Shared decision making; Assigned to Arm(s): Experimental group
B: Arm Label: spirometry, patient activation tool; Type: EXPERIMENTAL; Interventions: Other: provider support tools plus spirometer | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: provider support tools plus spirometer; Assigned to Arm(s): spirometry, patient activation tool
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Care Coordination | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Intervention
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention 1; Type: OTHER; Interventions: Other: Intervention 1 | Arm Label: Intervention 2; Type: OTHER; Interventions: Other: Intervention 2 | Intervention Type: OTHER; Name: Intervention 1; Assigned to Arm(s): Intervention 1 | Intervention Type: OTHER; Name: Intervention 2; Assigned to Arm(s): Intervention 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Programs of Coordinated Care and Disease Management
Brief Summary: This is a Congressionally mandated study. In the original study, 16 demonstration programs provided care coordination services to beneficiaries with chronic illness in Medicare's fee-for-service program. A five-year CMS-funded study tested whether the programs can improve patients' use of medical services, improve patients' outcomes and satisfaction with care, and reduce Medicare costs. The study also assessed physicians' satisfaction with the programs.

In 2008 Congress extended the project for two of the original programs--Mercy Medical Center - North Iowa and Health Quality Partners in Pennsylvania--and they will enroll Medicare beneficiaries and provide care coordination services into the spring of 2010.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
C: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Care Coordination | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dental Tobacco Control.Net:Improving Practice
Brief Summary: This is a randomized, controlled trial (RCT) to test the efficacy of an internet continuing dental education intervention designed to increase tobacco cessation counseling in dental practices. The intervention involves surveying practices regarding preventive care, surveying adult patients about their tobacco habits and preventive care provided by dental practice and training/educating the dentist and office staff on tobacco cessation. With patients who smoke and indicate that they have quit, we followed up with testing their saliva for the presence of cotinine. We have enrolled general dentists and periodontists who practice in the Southeastern United States.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
C: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
D: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dental Tobacco Control.Net:Improving Practice
Brief Summary: This is a randomized, controlled trial (RCT) to test the efficacy of an internet continuing dental education intervention designed to increase tobacco cessation counseling in dental practices. The intervention involves surveying practices regarding preventive care, surveying adult patients about their tobacco habits and preventive care provided by dental practice and training/educating the dentist and office staff on tobacco cessation. With patients who smoke and indicate that they have quit, we followed up with testing their saliva for the presence of cotinine. We have enrolled general dentists and periodontists who practice in the Southeastern United States.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMOKELESS TOBACCO AWARENESS PROGRAM | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMOKELESS TOBACCO AWARENESS PROGRAM; Assigned to Arm(s): Intervention
C: Arm Label: Control (Usual care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tobacco Cessation Tool (CATI Tool); Type: EXPERIMENTAL; Interventions: Behavioral: CATI Tool | Intervention Type: BEHAVIORAL; Name: CATI Tool; Assigned to Arm(s): Tobacco Cessation Tool (CATI Tool)
D: Arm Label: Obesity prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity Prevention | Arm Label: Tobacco prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Prevention | Intervention Type: BEHAVIORAL; Name: Obesity Prevention; Assigned to Arm(s): Obesity prevention | Intervention Type: BEHAVIORAL; Name: Tobacco Prevention; Assigned to Arm(s): Tobacco prevention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dental Tobacco Control.Net:Improving Practice
Brief Summary: This is a randomized, controlled trial (RCT) to test the efficacy of an internet continuing dental education intervention designed to increase tobacco cessation counseling in dental practices. The intervention involves surveying practices regarding preventive care, surveying adult patients about their tobacco habits and preventive care provided by dental practice and training/educating the dentist and office staff on tobacco cessation. With patients who smoke and indicate that they have quit, we followed up with testing their saliva for the presence of cotinine. We have enrolled general dentists and periodontists who practice in the Southeastern United States.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Fear of Food in Anorexia Nervosa
Brief Summary: This study will compare the effectiveness of two types of psychotherapy, a relapse prevention program and cognitive behavioral therapy, in reducing relapse and fear of eating situations in people with anorexia nervosa.


Options:
A: Arm Label: Family Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Family Behavior Therapy | Arm Label: Systems Family Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Family Therapy | Intervention Type: BEHAVIORAL; Name: Family Behavior Therapy; Assigned to Arm(s): Family Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Systems Family Therapy; Assigned to Arm(s): Systems Family Therapy
B: Arm Label: Cognitive behavioral counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Identity Intervention Program | Arm Label: Supportive therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Psychotherapy for the Eating Disorders | Intervention Type: BEHAVIORAL; Name: Identity Intervention Program; Assigned to Arm(s): Cognitive behavioral counseling | Intervention Type: BEHAVIORAL; Name: Supportive Psychotherapy for the Eating Disorders; Assigned to Arm(s): Supportive therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Family Based Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ego-Oriented Individual Psychotherapy | Intervention Type: BEHAVIORAL; Name: Family Based Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Ego-Oriented Individual Psychotherapy; Assigned to Arm(s): 2
D: Arm Label: Exposure and Response Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP) | Arm Label: Cognitive Behavior Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP); Assigned to Arm(s): Exposure and Response Prevention | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl)
Brief Summary: The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Buserelin and Pregnyl | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregnyl | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Buserelin and Pregnyl | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregnyl | Intervention Type: DRUG; Name: Buserelin and Pregnyl; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregnyl; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Buserelin and Pregnyl; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Pregnyl; Assigned to Arm(s): D
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: triptorelin acetate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Na Cl %0.9 | Intervention Type: DRUG; Name: triptorelin acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Na Cl %0.9; Assigned to Arm(s): 2
C: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin beta injection | Intervention Type: DRUG; Name: corifollitropin alfa; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Follitropin beta injection; Assigned to Arm(s): 4

Answer: A